{"filing":{"accession_number":"0001193125-26-257733","cik":"0001798749","ticker":"JBIO","company_name":"Jade Biosciences, Inc.","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"d103726d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1798749/000119312526257733/d103726d8k.htm"},"events":[{"id":6838,"run_id":5989,"accession_number":"0001193125-26-257733","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Jade Biosciences entered into an underwriting agreement on June 3, 2026 to issue and sell 10,000,000 shares of common stock at $15.00 per share, with expected net proceeds of approximately $140.3 million (or $161.5 million if the underwriters' 30-day option is exercised in full). This is a registered public offering of equity securities that will dilute existing shareholders. The disclosure of the underwriting agreement, pricing, and expected proceeds is characteristic of a dilutive equity issuance material to investors.","company_name":"Jade Biosciences, Inc.","ticker":"JBIO","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":[{"id":4372,"accession_number":"0001193125-26-257733","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Jade Biosciences entered into an underwriting agreement on June 3, 2026 to issue and sell 10,000,000 shares of common stock at $15.00 per share, with expected net proceeds of approximately $140.3 million (or $161.5 million if the underwriters' 30-day option is exercised in full). This is a registered public offering of equity securities that will dilute existing shareholders. The disclosure of the underwriting agreement, pricing, and expected proceeds is characteristic of a dilutive equity issuance material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:00:07.374511+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4372,"accession_number":"0001193125-26-257733","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Jade Biosciences entered into an underwriting agreement on June 3, 2026 to issue and sell 10,000,000 shares of common stock at $15.00 per share, with expected net proceeds of approximately $140.3 million (or $161.5 million if the underwriters' 30-day option is exercised in full). This is a registered public offering of equity securities that will dilute existing shareholders. The disclosure of the underwriting agreement, pricing, and expected proceeds is characteristic of a dilutive equity issuance material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:00:07.374511+00:00","company_name":"Jade Biosciences, Inc.","ticker":"JBIO","filing_date":"2026-06-04"}]}